Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
So, your drug has reached the post-approval phase of its lifecycle, and you may be wondering, what comes next? Though the road to drug approval is long and rife with challenges, the post-approval phase comes with its own unique demands, including possible market expansion, evolving dosages and indications, and chemistry, manufacturing, and control (CMC) updates. Your team will need experts that can handle a wide variety of renewals and administrative tasks, especially if you are operating across multiple global jurisdictions. To start your journey successfully, familiarize yourself with what post-approval management demands. From there, assess what approach works best for your goals.
Proactive and effective lifecycle management will require either in-house or external experts that can handle the following tasks: renewals, CMC variations, labeling updates, regulatory information data management, and marketing authorization transfers and withdrawals. To work effectively with regulatory bodies, you will need to establish a thoughtful approach that entails the following:
Since the prospect of effective lifecycle management and regulatory strategy across multiple global jurisdictions can be daunting, many companies opt to work with a regulatory services provider as well as local qualified persons for pharmacovigilance (LQPPVs), who are now required in more than 40 countries.
A QPPV and LCM services provider can provide guidance in a variety of areas, including insight into market application expansion as well as end-to-end support for lifecycle management. Their team can also provide access to LQPPVs across multiple jurisdictions, and with access to a network of knowledgeable LQPPVs, your team can benefit from a variety of holistic solutions, including:
These benefits are only the beginning of what is possible when you partner with a qualified regulatory services provider and gain access to LQPPVs.
In a recent webinar, IQVIA experts, Vera Dinis, Regulatory Affairs Director, and Ana Pedro Jesuíno, Marketed Product Safety Associate Director, discussed their recommendations for navigating post-approval management, building an effective regulatory approach, and tackling post-approval regulatory obstacles, including divergent health authority expectations and supply chain disruptions. If you are looking for an effective map to traverse your drug’s post-approval lifecycle, download the full white paper, Effective Strategies for Post-approval Lifecycle Management and Local Pharmacovigilance.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
Harness the power of automation to execute streamlined end-to-end safety solutions while reducing costs.
Reimagine regulatory service delivery.
Harness the power of global human expertise combined with automation, artificial intelligence (AI) and machine learning (ML) to design, build and execute end-to-end safety solutions.